ERBB2 and cancer: Therefore, inhibiting HER2 activity through the administration of trastuzumab, a highly purified recombinant DNA‐derived IgG1 kappa Mab binding specifically to the extracellular domain of HER2 receptor, would provide a new promising approach to cancer therapy.72